If you look at that CASE STUDY: ROADMAP TO CASH FLOW POSITIVE...

If you look at that CASE STUDY: ROADMAP TO CASH FLOW POSITIVE they are still sticking to that timeline of Q4 CY24. So 7 months from now is not that long in the scheme of things. 80k patients to cash flow positive, whether that's a combination of sensor sales and data fees we don't know.
But Imo there would be a good chance they would know by now if that target was still achievable, and now would be the time to push that target out if it was not. So I can only assume they are still confident of that short term goal.
If you look at various timeline graphs on the progress of bio techs, it certainly looks like to me we are nearing the end of the valley of death stage.
I certainly don't mind topping up and averaging down at these levels but it's the up coming consolidation and post consolidation that's making me bork. If it wasn't for that variable I would still be accumulating and hoping for the best. .003c will mean .045c. Then a possible cap raise to follow. Time to buy a crystal ball on Ebay.